Management Team

Brings to all projects over 30 years of industry experience from leading small, medium and large pharmaceutical companies.

Dan Vickery, M.B.A., Ph.D.
Founder & President

Carolyn Myers, M.B.A., Ph.D.


Dan Vickery, M.B.A., Ph.D.

Dr. Vickery is a Pharmaceutical Business Development Consultant and President of BioEnsemble, Ltd., a firm which provides general management, strategic development and commercialization expertise especially in the therapeutic areas of Urology, Immunology, Cardiovascular, CNS, WHC and Special Dosage Forms/Drug Delivery, to help promising technologies and companies enhance their strategic direction to find development partners and sources of funding. 

Dr. Vickery is currently on the board of Urigen Pharmaceuticals, Inc. and has also acted as CEO, President, Chairman and managing consultant for that company. He is an advisory board member of the Center for Molecular Medicine and Therapeutics and a board member of Interstial Cystitis Association. He is also a President's Circle member of the American Association for the Advancement of Science (AAAS) and of the Licensing Executive’s Society (LES).

Prior to starting his consulting practice in 2005, he held a senior business development position at Mylan Pharmaceuticals, overseeing their Branded Products and Drug Delivery divisions, during which he focused on transactions for Drug Delivery products in the EU, and in-licensing and out-licensing of branded products. 

Prior to joining Mylan, Dr. Vickery had worldwide commercial development responsibility at Pharmacia for the therapeutic areas of Urology, Women’s Health Care, and Sexual Dysfunction. 

He also has significant experience in development, having lead the Regulatory Affairs department at Parke-Davis division, Warner-Lambert, during the time in which Lipitor was approved and launched.

Carolyn Myers, M.B.A., Ph.D.​

Dr. Myers is an accomplished pharmaceutical executive with extensive experience optimizing productivity, creating value and increasing profitability. She has broad general management, business development and commercial expertise in US and global markets, and is adept at developing strategic plans and translating them into actionable objectives that drive performance and growth.

In her most recent position as Vice President, Global Alliance Management & International Brand Business Development at Allergan (NYSE: AGN), Dr. Myers led an Alliance Management team that managed over 150 partners, representing a sizeable portion of Allergan’s promoted and development product portfolio. In her BD role, she led development of ex-US business development strategy, and directed the evaluation and ultimate negotiation of business development opportunities. Earlier, Dr. Myers was Vice President, CNS Marketing at Forest Laboratories (acquired by Allergan in 2015), where she managed the marketing team responsible for CNS brands with $2.5B in annual sales (about 75% of company revenue in 2011). She directed the creation and execution of brand strategies and tactics for marketed brands, for new product launches and for brands in development.

Before joining Allergan, Dr. Myers was President at Dey Laboratories, Mylan’s branded business unit, which had about $580M in sales and more than 300 employees. She managed the entire business unit, including strategic and long-range planning, sales and marketing, clinical development, manufacturing and distribution. During her tenure, she achieved EBITDA growth of 80% in 2009, 28% in 2010 and 26% in 2011. Previously, she was President of Mylan Technologies, a developer and manufacturer of generic and branded transdermal products. She led the prioritization of the drug development pipeline, which ultimately led to FDA approval of three key transdermal products, and directed various BD deals, including licensing the EMSAM® patch to Bristol-Myers Squibb. She also was Vice President, Business Development & Strategic Marketing, working with senior leadership to enhance Mylan’s branded business strategy. 

She is a member of Mid Atlantic Bio Angels, a member of AAAS and a board member at the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.

About Us
Advisory Board

Carlo Di Fonzo
Vice President, Drug Development & Regulatory Affairs Nektar Therapeutics

Brad Hossack
Vice President, Stryker

Dalal Manoli
President​ DMCC Consuting

Robert Milne
Director, Drug Safety​, EMD Serono